Genta assesses direction after disappointing melanoma trial
This article was originally published in Scrip
Executive Summary
Genta's troubled novel antisense lead drug candidate Genasense (oblimersen sodium) has failed to meet one of its primary endpoints, progression-free survival (PFS), in a pivotal, first-line Phase III AGENDA trial in advanced melanoma. The company said it was assessing the impact of these data – which will preclude a filing this year – on its strategic direction. Overall survival data will not be mature for another year or so.